1
|
Rastkar M, Ghajarzadeh M, Sahraian MA. Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports. CURRENT JOURNAL OF NEUROLOGY 2023; 22:115-136. [PMID: 38011449 PMCID: PMC10460926 DOI: 10.18502/cjn.v22i2.13340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/10/2022] [Accepted: 02/05/2023] [Indexed: 11/29/2023]
Abstract
Background: Glatiramer acetate (GA) and Interferon (IFN) beta-1a are used as first-line disease-modifying treatments for multiple sclerosis (MS). In this systematic review, we summarized case reports and case series of adverse side effects of GA and IFN beta-1a in MS patients. Methods: Without any restrictions, PubMed, Scopus, Web of Sciences, and Embase databases, and gray literature were systemically searched until June 2022. Articles were screened and data were extracted based on a predefined table by two independent reviewers. The risk of bias was assessed using the Joanna Briggs Institute (JBI) tool. Results: We identified 2103 records from the preliminary search. After deduplication and screening, 172 articles were included in the systematic review. In total, 229 individuals (52 men, 173 women, and 4 unknown) were included in the study. The most common adverse events were cutaneous (32.75%), hepatic (13.54%), allergic (8.3%), and neurological (5.68%) side effects. Furthermore, most reported side effects were related to autoimmune diseases or hypersensitivity reactions. Conclusion: GA and IFN beta-1a are associated with several side effects which may be related to the immunomodulatory function of medication or other injection-related reactions.
Collapse
Affiliation(s)
- Mohsen Rastkar
- Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Mahsa Ghajarzadeh
- Multiple Sclerosis Research Center, Neuroscience institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Mohammad Ali Sahraian
- Multiple Sclerosis Research Center, Neuroscience institute, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
2
|
Alugba G, Urhi A, Olateju IV, Onyemarin H, Uzzi C, Oshiba-Fowode T, Obomanu E, Popoola HA, Okoronkwo EJ, Ukenenye E, Asaolu G, Oladunjoye AF, Oladunjoye O. Renal diseases associated with multiple sclerosis: A narrative review. Medicine (Baltimore) 2022; 101:e31959. [PMID: 36482579 PMCID: PMC9726425 DOI: 10.1097/md.0000000000031959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The mechanisms of renal pathology in multiple sclerosis (MS) can be related to the disease itself or its treatment. Although kidney disease can be associated with MS, not much has been reported in the literature; hence, our study aimed to describe the prevalence and types of renal diseases and discuss their prognosis in patients with MS. A literature search (2012-2022) was performed using the Scale for the Assessment of Narrative Review Articles. The databases searched included MEDLINE (PubMed) and EMBASE. Fourteen articles from these databases met the inclusion criteria. The inclusion criteria were as follows: publications with full-text access. Articles published in English. Original articles related to renal diseases in MS. The prevalence of renal diseases in MS from the articles obtained ranged from 0.74% to 2.49%. Interferon beta (IFN-β)-associated glomerulonephritis was common among the reviewed articles. Significant improvement and resolution of the pathology were observed after the discontinuation of the offending medication. Renal symptoms in 2 out of 4 cases with renal thrombotic microangiopathy (TMA) induced by interferon-beta progressed to chronic kidney disease, even after the drug was stopped. Other studied renal pathologies included nephrolithiasis secondary to urinary retention and urinary catheter use in patients with MS.
Collapse
Affiliation(s)
- Gabriel Alugba
- Delta State University, Abraka, Nigeria
- * Correspondence: Gabriel Alugba, Delta State University, P.M.B 1 Abraka, Delta State, Nigeria (e-mail: )
| | | | | | | | | | | | - Elvis Obomanu
- Department of Medicine, University of Portharcourt, Choba, Nigeria
| | | | | | - Emmanuel Ukenenye
- Medical Council of Jamaica, University of the West Indies, Kingston, Jamaica
| | - Gideon Asaolu
- Medical Council of Jamaica, University of the West Indies, Kingston, Jamaica
| | | | - Olubunmi Oladunjoye
- Department of General Internal Medicine, Baylor College of Medicine, Houston, TX, USA
| |
Collapse
|
3
|
Soleimani B, Murray K, Hunt D. Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis. Drug Saf 2020; 42:941-956. [PMID: 30830572 DOI: 10.1007/s40264-019-00799-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Biologic immunotherapies have transformed the treatment landscape of multiple sclerosis. Such therapies include recombinant proteins (interferon beta), as well as monoclonal antibodies (natalizumab, alemtuzumab, daclizumab, rituximab and ocrelizumab). Monoclonal antibodies show particular efficacy in the treatment of the inflammatory phase of multiple sclerosis. However, the immunological perturbations caused by biologic therapies are associated with significant immunological adverse reactions. These include development of neutralising immunogenicity, secondary immunodeficiency and secondary autoimmunity. These complications can affect the balance of risks and benefits of biologic agents, and 2018 saw the withdrawal from the market of daclizumab, an anti-CD25 monoclonal antibody, due to concerns about the development of severe, unpredictable autoimmunity. Here we review established and emerging risks associated with multiple sclerosis biologic agents, with an emphasis on their immunological adverse effects. We also discuss the specific challenges that multiple sclerosis biologics pose to drug safety systems, and the potential for improvements in safety frameworks.
Collapse
Affiliation(s)
| | - Katy Murray
- Anne Rowling Clinic, University of Edinburgh, Edinburgh, UK
| | - David Hunt
- Anne Rowling Clinic, University of Edinburgh, Edinburgh, UK. .,MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
| |
Collapse
|
4
|
Tatar E, Cengiz Y, Pektas E, Eroglu B, Turkeri Birant G, Tasli F. Interferon-β therapy and C4d glomerulopathy: Case report and literature review. Nephrology (Carlton) 2019; 25:507-508. [PMID: 31775180 DOI: 10.1111/nep.13675] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Revised: 10/23/2019] [Accepted: 10/27/2019] [Indexed: 11/30/2022]
Affiliation(s)
- Erhan Tatar
- Department of Nephrology, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
| | - Yalcın Cengiz
- Department of Internal Medicine, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
| | - Erengul Pektas
- Department of Internal Medicine, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
| | - Busra Eroglu
- Department of Internal Medicine, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
| | - Gulen Turkeri Birant
- Department of Nephrology, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
| | - Funda Tasli
- Department of Pathology, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
| |
Collapse
|
5
|
Ozturk M, Basoglu F, Yilmaz M, Ozagari AA, Baybas S. Interferon β associated nephropathy in a Multiple Sclerosis patient: A case and review. Mult Scler Relat Disord 2016; 9:50-3. [PMID: 27645343 DOI: 10.1016/j.msard.2016.06.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2016] [Revised: 04/12/2016] [Accepted: 06/25/2016] [Indexed: 02/06/2023]
Abstract
BACKGROUND Interferon beta (IFN β) subtypes are largely used as immunomodulatory agents in Multiple Sclerosis (MS) treatment. While being generally well tolerated, they can cause various side effects. Adverse effects related to kidney are rarely reported. CASE REPORT We report a 32 years old male patient who developed nephrotic syndrome while receiving IFN β for MS. Biopsy showed focal segmental glomerulosclerosis. He went into remisson after cessation of drug and with the aid of angiotensin II antagonists. Here, we report this case and a review of similar cases reported in literature. CONCLUSIONS Although it's a rare adverse effect and tend to show good prognosis physicians should pay careful attention to symptoms and findings of nephropathy during follow ups of patients under treatment with these agents.
Collapse
Affiliation(s)
- Musa Ozturk
- Department of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Tevfik Saglam Cad No:25/2, 34147 Bakirkoy, Istanbul, Turkey.
| | - Fulya Basoglu
- Department of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Tevfik Saglam Cad No:25/2, 34147 Bakirkoy, Istanbul, Turkey.
| | - Murvet Yilmaz
- Department of Nephrology, Bakirkoy Dr Sadi Konuk Reasaerch and Training Hospital, Tevfik Saglam Street No:11, 34147 Bakirkoy, Istanbul, Turkey.
| | - Ayse Aysim Ozagari
- Department of Pathology, Sisli Hamidiye Etfal Research and Training Hospital, Halaskargazi Boulevard, Etfal Street, 34360 Sisli, Istanbul, Turkey.
| | - Sevim Baybas
- Department of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Tevfik Saglam Cad No:25/2, 34147 Bakirkoy, Istanbul, Turkey.
| |
Collapse
|